Foldax Named Cardiovascular Device Company of the Year by MedTech Outlook

By October 13, 2020 December 13th, 2020 News

Foldax® announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine. Foldax was honored for its innovative Tria™ heart valve, the first biopolymer heart valve to receive FDA approval for a U.S. clinical trial.

Foldax has reinvented every aspect of the artificial heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime that address historical tradeoffs. The Tria heart valve is made with its proprietary LifePolymer™ biopolymer that, combined with an innovative valve design, is intended to eliminate calcification, withstand stresses and strains in the heart without failure, and restore patient quality of life without lifelong anticoagulant use.

Tria is also the first and only heart valve to be robotically manufactured, reducing variability and enabling high precision, repeatability and quality, while substantially improving the economics of heart valve manufacturing.

“We take pride in honoring Foldax as our Company of the Year among 10 finalists specializing in Cardiovascular Device Solutions,” said Alex D’souza, Managing Editor of MedTech Outlook.

“We are thrilled to be honored with another award recognizing our Tria heart valve technology. It reinforces our commitment to reimagining how heart valves are made and improving upon currently available options. We look forward to continuing the clinical trial for our surgical aortic valve and initiating clinical study of our surgical mitral valve later this year,” stated Ken Charhut, Executive Chairman of Foldax.